Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 5/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8336651 | 0.81 | KMT2A (0.46) | KCNK3KMT2AMEN1KDM4EMAPT | |
| SCHEMBL20153393 | 0.81 | KCNK3 (0.42) | KCNK3KCNK9KMT2AMEN1KDM4E | |
| SCHEMBL23462651 | 0.79 | KCNK3 (0.39) | KCNK3KCNK9KMT2AMEN1KDM4E | |
| SCHEMBL6108573 | 0.79 | KCNK3 (0.42) | KCNK3KCNK9KMT2AMEN1KDM4E | |
| SCHEMBL6108575 | 0.79 | KCNK3 (0.42) | KCNK3KCNK9KMT2AMEN1KDM4E | |
| SCHEMBL5091415 | 0.79 | NNMT (0.46) | KCNK3KCNK9KMT2AMEN1KDM4E | |
| SCHEMBL7081677 | 0.79 | NNMT (0.46) | KCNK3KCNK9KMT2AMEN1KDM4E | |
| SCHEMBL23558962 | 0.78 | OXTR (0.39) | KCNK3KCNK9KMT2AMEN1KDM4E | |
| SCHEMBL17262997 | 0.77 | ADRB3 (0.38) | KCNK3KCNK9KMT2AMEN1KDM4E | |
| SCHEMBL13719466 | 0.77 | ADRB3 (0.38) | KCNK3KCNK9KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110167933-B | As αVAzole amides and amines as integrin inhibitors | 百时美施贵宝公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3538527-B1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3538527-B1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3538527-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018089358-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089358-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | ITGAV, ITGB1, ITGA1 | KCNK3 1847/4885KCNK9 1064/4885KMT2A 2129/4885 |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | KCNK3 1847/4885KCNK9 1064/4885KMT2A 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.